Article
Synthetic Biology Drug Products — CMC Regulatory Landscape for Engineered Microorganism Therapeutics
An engineered bacterium that produces a therapeutic protein inside the patient's gut is simultaneously a live biotherapeutic product, a gene-therapy-adjacent vector, and a local drug delivery system. It…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Synthetic Biology Drug Products — CMC Regulatory Landscape for Engineered Microorganism Therapeutics
An engineered bacterium that produces a therapeutic protein inside the patient's gut is simultaneously a live biotherapeutic product, a gene-therapy-adjacent vector, and a local drug delivery system. It…
Article
CAR-NK and Next-Generation Engineered Cell Products — CMC at the Cell-Gene Therapy Convergence
CAR-NK cell therapy solves the most significant commercial limitation of CAR-T: patient specificity. An allogeneic CAR-NK product can be manufactured from a single cord blood unit, expanded to…
Article
Warning Letter Response — CMC Strategy Before the 15-Day Clock Starts
This distinction is not semantic. It is the difference between a response that closes a Warning Letter in a single review cycle and one that triggers an escalation…
Article
3.2.S.4 Drug Substance Specifications, Analytical Methods, and Validation: The Complete Testing Package
The specification table in 3.2.S.4.1 is the single most scrutinized document in a drug substance CMC submission. Every limit must be scientifically justified, every method must be validated…
Article
Module 3 Authorship — The Method That Gets CMC Packages Approved
The CMC package FDA receives is not evaluated solely on the science it contains — it is evaluated on whether the scientific narrative is coherent, internally consistent, and…
Article
3.2.S.3.2 Drug Substance Impurities: Writing the ICH Q3A-Compliant Impurity Profile FDA Will Accept
"ICH Q3A(R2) sets reporting, identification, and qualification thresholds for drug substance impurities that have been in force since 2006. Nearly two decades later, the most common impurity-related deficiency…
Article
The Ionizable Lipid pKa Principle: Why the Chemistry You Select at Formulation Development Becomes the CQA You Cannot Escape at BLA
The apparent pKa of the ionizable lipid component is not a routine physicochemical descriptor. It is the master variable from which endosomal escape efficiency, organ biodistribution, immune activation…
Article
3.2.S.3.1 Elucidation of Structure: Building the Analytical Evidence Package That Proves Your Compound Is What You Say It Is
A structural-elucidation package is not simply a collection of spectra. It is an integrated identity argument showing that the material described in the dossier is the drug substance…
Article
Data Integrity Warning Letter Remediation: Rebuilding Credibility After a GMP Finding
A data integrity Warning Letter is not a documentation problem — it is a credibility crisis, and the difference between companies that recover in 18 months and those…
Article
3.2.S.2.4–2.6 Critical Steps, Process Validation, and Manufacturing Process Development: Building the Process Understanding Evidence Package
A recurring CMC review issue is not the absence of process information, but the absence of a coherent evidentiary bridge between critical-step controls, process validation or evaluation, and…
Article
GMP Remediation — XGene’s Structured Framework for 483 Responses
Most 483 responses fail not because the company failed to address the observation — but because the response addressed the symptom FDA described while leaving the quality system…
Article
3.2.S.2.3 Control of Materials: The Starting Material Justification That FDA and EMA Scrutinize Most
"The starting material designation for a new drug substance is among the most consequential regulatory decisions in CMC development. It defines the boundary of GMP applicability, the scope…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.